University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Eric A. Collisson, MD

Eric A. Collisson, MD

Associate Professor in Residence, Department of Medicine, UCSF

Cancer Center Program Memberships

Cancer Genetics

Research Summary

I am a medical oncologist with a specific interest in the genomics of cancer. My laboratory uses a variety of techniques to interrogate three basic themes in the biology and clinical behavior of these deadly cancers: (1) intra- patient tumor heterogeneity at the temporal and anatomic levels, (2) inter-patient heterogeneity between different patients, and (3) tumor-microenvironmental interactions. We use a combination of genetically engineered mouse models, cell lines, and clinically derived samples to interrogate multiple genomic outputs with a focus on genomic DNA and mRNA.

Education

UC Berkeley, BA, 1996 Genetics
UC Los Angeles, MD, 2002, Medicine
 


Professional Experience

  • 2003-2005
    Intern and Resident, Internal Medicine, Stanford University Hospital
  • 2005-2008
    Clinical Fellowship, Heme/Onc, UCSF
  • 2008-2009
    Post Doctoral Fellow, Lawrence Berkeley National Labs
  • 2009-2010
    Instructor, Hematology/Oncology, UCSF
  • 2010-present
    Associate Professor in Residence, Hematology/Oncology, UCSF

Honors & Awards

  • 1999
    Howard Hughes Medical Institute-NIH Research Scholar, Bethesda MD., Howard Hughes Medical Inst./NIH
  • 2001
    Alpha Omega Alpha, UCLA Chapter, AOA, UCLA
  • 2006
    Amgen Scholar, Amgen Foundation
  • 2007
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2012
    AACR PanCAN Career Development Award, American Association of Cancer Research
  • 2013
    Clinical Scholar Development Award , Doris Duke Charitable Foundation

Selected Publications

  1. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019 Feb 04.
    View on PubMed
  2. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2018 Sep 28.
    View on PubMed
  3. Collisson EA. Bringing Pancreas Cancer into the Lab. Cancer Discov. 2018 Sep; 8(9):1062-1063.
    View on PubMed
  4. Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med. 2018 Aug 22; 10(455).
    View on PubMed
  5. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Nov; 211(5):1010-1019.
    View on PubMed
  6. Jha P, Yeh BM, Zagoria R, Collisson E, Wang ZJ. The Role of MR Imaging in Pancreatic Cancer. Magn Reson Imaging Clin N Am. 2018 Aug; 26(3):363-373.
    View on PubMed
  7. North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018 05 14; 9(1):1894.
    View on PubMed
  8. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 Sep; 23(9):998-1003.
    View on PubMed
  9. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018; 2018.
    View on PubMed
  10. Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J. 2017 Nov/Dec; 23(6):315-320.
    View on PubMed
  11. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786.
    View on PubMed
  12. Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One. 2017; 12(10):e0186551.
    View on PubMed
  13. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
    View on PubMed
  14. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505.
    View on PubMed
  15. Collisson EA, Maitra A. Pancreatic Cancer Genomics 2.0: Profiling Metastases. Cancer Cell. 2017 03 13; 31(3):309-310.
    View on PubMed
  16. Collisson EA, Olive KP. Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field. Cancer Res. 2017 03 01; 77(5):1060-1062.
    View on PubMed
  17. Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans RM. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1129-1134.
    View on PubMed
  18. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
    View on PubMed
  19. Cho RJ, Collisson EA. Election 2016: Voting on Variants. Cancer Discov. 2016 07; 6(7):694-6.
    View on PubMed
  20. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52.
    View on PubMed

Go to UCSF Profiles, powered by CTSI